Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Outlook Therapeutics, Inc.NASDAQ: OTLK

EBITDA · Q2 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$14M, compared with -$12.36M a year earlier. Trailing-twelve-month EBITDA was -$62.08M.

Context

  • EBITDA amounted to 4497.7% of revenue in FY2025.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of -$10.09M (+84.1%) for the fiscal year ending Sep 2026, a step up from the +11.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14M-4.0% QoQ
Last fiscal yearSep 2025
-$63.58M+11.8% YoY
LTMMar 2026
-$62.08M-482.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.2%+45.6%+58.8 pp
1 year+11.8%+84.1%+72.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(63.58M) USD
Year-over-year change
+11.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 EBITDA of -$62.08M is the 8th highest of the 9 companies compared; the peer median is -$22.67M.
  • Its year-over-year change of -482.8% is the 8th highest of 9, against a peer median of -4.9%.
  • EBITDA amounts to 18634.1% of revenue for OTLK, versus a peer median of 436.9%.
OTLK Competitors Peer median
EBITDA for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-$10.87M -9.4%—769.0%
CUECue Biopharma, Inc.LTM Mar 2026-$15.84M +57.4%—48.4%
EQEquillium, Inc.LTM Mar 2026-$18.95M -40.5%——
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026-$22.02M +66.8%—104.8%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$23.33M -0.3%—1017.5%
OSTXOS Therapies IncorporatedLTM Mar 2026-$34.71M -256.5%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026-$36.2M +34.4%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.08M -482.8%—18634.1%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$89.9M -1211.1%——
Peer median (excluding OTLK) -$22.67M-4.9%—436.9%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.